![conference banner](/images/conference-banner.jpeg)
Abstract
An increasing number of patients receive anticoagulant therapy to prevent and treat arterial or venous thromboembolism. The major complication of anticoagulant therapy is the increase of the individual bleeding risk. All anticoagulant drugs can cause haemorrhages, that can sometimes be life-threatening. Although heparins and the vitamin K antagonists have been the most widely used anticoagulants for decades, the correct management of bleeding complications associated with these agents has been poorly studied. More recently, new anticoagulant drugs, both parenteral and oral, have been approved for clinical use. Currently, none of these new agents has a specific antidote, and little advise can be given on how to manage a major bleeding event. The aim of this article is to describe the haemorrhagic risk and the management of bleeding complications associated with the principal anticoagulant drugs.
Keywords: Anticoagulants, bleeding, vitamin k antagonists, dabigatran, rivaroxaban, heparin, fondaparinux, venous thromboembolism, anticoagulant therapy, heparins, transfusion, Thrombosis, Hemostasis, Interna-tional normalized Ratio, VKA, hepatic disease, hypertension, malignancy, haematological disease, thromboembolic risk, VKAs therapy, INR monitoring, American College of Chest Physicians, warfarin therapy, acenocoumarol, phenopro-coumon, Antifibrinolytic drugs, tranexamic acid, fresh frozen plasma, recombinant factor VIIa, Prothrombin Complex Concentrates, liver disease, haemophilia, anti-Xa activity, Protamine Sulfate
Current Pharmaceutical Design
Title: Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants
Volume: 16 Issue: 31
Author(s): Erica Romualdi, Elena Rancan, Sergio Siragusa and Walter Ageno
Affiliation:
Keywords: Anticoagulants, bleeding, vitamin k antagonists, dabigatran, rivaroxaban, heparin, fondaparinux, venous thromboembolism, anticoagulant therapy, heparins, transfusion, Thrombosis, Hemostasis, Interna-tional normalized Ratio, VKA, hepatic disease, hypertension, malignancy, haematological disease, thromboembolic risk, VKAs therapy, INR monitoring, American College of Chest Physicians, warfarin therapy, acenocoumarol, phenopro-coumon, Antifibrinolytic drugs, tranexamic acid, fresh frozen plasma, recombinant factor VIIa, Prothrombin Complex Concentrates, liver disease, haemophilia, anti-Xa activity, Protamine Sulfate
Abstract: An increasing number of patients receive anticoagulant therapy to prevent and treat arterial or venous thromboembolism. The major complication of anticoagulant therapy is the increase of the individual bleeding risk. All anticoagulant drugs can cause haemorrhages, that can sometimes be life-threatening. Although heparins and the vitamin K antagonists have been the most widely used anticoagulants for decades, the correct management of bleeding complications associated with these agents has been poorly studied. More recently, new anticoagulant drugs, both parenteral and oral, have been approved for clinical use. Currently, none of these new agents has a specific antidote, and little advise can be given on how to manage a major bleeding event. The aim of this article is to describe the haemorrhagic risk and the management of bleeding complications associated with the principal anticoagulant drugs.
Export Options
About this article
Cite this article as:
Romualdi Erica, Rancan Elena, Siragusa Sergio and Ageno Walter, Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563329
DOI https://dx.doi.org/10.2174/138161210793563329 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin
Current Pharmaceutical Design Clinical Evaluation of Natural History of Peyronie’s Disease: Our Experience, Old Myths and New Certainties
Inflammation & Allergy - Drug Targets (Discontinued) CD45 Regulated Signaling Pathways
Current Topics in Medicinal Chemistry Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration
Mini-Reviews in Medicinal Chemistry The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Adeno-Associated Virus-Mediated Gene Transfer in Hematopoietic Stem/Progenitor Cells as a Therapeutic Tool
Current Gene Therapy Recent Advances and Patents on Coronary Sinus Perfusion Devices for Treatment of Heart Disease
Recent Patents on Biomedical Engineering (Discontinued) A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP
Current Alzheimer Research The Thiol-polyamine Metabolism of Trypanosoma cruzi: Molecular Targets and Drug Repurposing Strategies
Current Medicinal Chemistry Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms
Current Drug Targets Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Narcolepsy in Adolescents: A Review and Three Case Reports
Adolescent Psychiatry Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Screening, Evaluation, and Early Management of Acute Aortic Dissection in the ED
Current Cardiology Reviews The Clinical Utility of Bivalirudin in Patients with Coronary Artery Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Design, Synthesis and Biological Evaluation of Scutellarein Derivatives as Potential Anti-Alzheimers Disease Candidates Based on Metabolic Mechanism
Letters in Drug Design & Discovery Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design